Analyst Price Targets — KALV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 10:05 am | Andrew Fein | H.C. Wainwright | $27.00 | $26.66 | TheFly | KalVista downgraded to Neutral from Buy at H.C. Wainwright |
| April 29, 2026 10:26 pm | — | Leerink Partners | $27.00 | $26.67 | TheFly | KalVista downgraded to Market Perform from Outperform at Leerink |
| January 9, 2026 11:09 am | Andrew Fein | H.C. Wainwright | $37.00 | $15.82 | TheFly | KalVista price target raised to $37 from $27 at H.C. Wainwright |
| January 6, 2026 12:42 pm | — | Needham | $32.00 | $15.66 | TheFly | KalVista price target raised to $32 from $28 at Needham |
| November 11, 2025 10:50 am | — | JMP Securities | $28.00 | $10.89 | TheFly | KalVista price target lowered to $28 from $29 at Citizens JMP |
| November 5, 2024 12:09 pm | Serge Belanger | Needham | $28.00 | $11.25 | StreetInsider | Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham |
| September 6, 2024 6:54 am | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV) |
| September 6, 2024 6:35 am | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV) |
| July 8, 2022 4:29 am | — | Needham | $38.00 | $10.98 | Benzinga | Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $38 |
Latest News for KALV
PARMA, Italy & FRAMINGHAM, Mass.--(BUSINESS WIRE)--Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, today announced the completion of its acquisition of KalVista Pharmaceuticals, Inc. (“KalVista”). KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of…
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
This clinical-stage biotech focused on rare diseases reported a notable insider sale amid a year of strong stock performance.
[url="]KalVista Pharmaceuticals[/url], Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALV.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.